Compound Kushen Injection Inhibits Immune Evasion in Hepatocellular Carcinoma via PD-L1 O-GlcNAcylation
Compound Kushen Injection (CKI) inhibits glycolysis and immune evasion in HCC cells by reducing O-GlcNAcylation of PD-L1.
Asset / Drug
Drug and asset intelligence for Compound with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.